机构:[1]Geriatric Hospital Afliated to Wuhan University of Science and Technology, Wuhan, China[2]Brain Science and Advanced Technology Institute, School of Medicine, Wuhan University of Science and Technology, Wuhan, China[3]School of Public Health, Wuhan University of Science and Technology, Wuhan, China[4]Department of Neurology and National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China[5]Department of Neurology, Fujian Medical University Union Hospital, and Fujian Key Laboratory of Molecular Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, China[6]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China神经科系统神经内科首都医科大学宣武医院[7]Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China[8]Computer Science and Technology, Wuhan University of Science and Technology, Wuhan, China[9]Department of Laboratory Medicine, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, China[10]Wuchang Hospital afliated to Wuhan University of Science and Technology, Wuhan, China
BackgroundAlzheimer's disease (AD), the most common type of irreversible dementia, is predicted to affect 152 million people by 2050. Evidence from large-scale preventive randomized controlled trials (RCTs) on modifiable risk variables in Europe has shown that multi-domain lifestyle treatments for older persons at high risk of dementia may be practical and effective. Given the substantial differences between the Chinese and European populations in terms of demographics and living conditions, direct adoption of the European program in China remains unfeasible. Although a RCT has been conducted in China previously, its participants were mainly from rural areas in northern China and, thus, are not representative of the entire nation.There is an urgent need to establish cohorts that represent different economic, cultural, and geographical situations in order to explore implementation strategies and evaluate the effects of early multi-domain interventions more comprehensively and accurately.MedtodsWe developed an integrated intervention procedure implemented in urban neighborhood settings, namely China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI). CHINA-IN-MUDI is a 2-year multicenter open-label cluster-randomised controlled trial centered around a Chinese-style multi-domain intervention to prevent cognitive decline. Participants aged 60-80 years were recruited from a nationally representative study, i.e. China Healthy Aging and Dementia Study cohort. An external harmonization process was carried out to preserve the original FINGER design. Subsequently, we standardized a series of Chinese-style intervention programs to align with cultural and socioeconomic status. Additionally, we expanded the secondary outcome list to include genomic and proteomic analyses. To enhance adherence and facilitate implementation, we leveraged an e-health application.ResultsScreening commenced in July 2022. Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193). Both the intervention and control groups exhibited similar baseline characteristics. Several lifestyle and vascular risk factors were present, indicating a potential window of opportunity for intervention. The intervention will be completed by 2025.ConclusionsThis project will contribute to the evaluation of the effectiveness and safety of intervention strategies in controlling AD risk and reducing clinical events, providing a basis for public health decision-making in China.
基金:
Science and Technology Innovation 2030 Major Projects [2022ZD0211600]; National Natural Science Foundation of China [82171491]
第一作者机构:[1]Geriatric Hospital Afliated to Wuhan University of Science and Technology, Wuhan, China[2]Brain Science and Advanced Technology Institute, School of Medicine, Wuhan University of Science and Technology, Wuhan, China[3]School of Public Health, Wuhan University of Science and Technology, Wuhan, China
共同第一作者:
通讯作者:
通讯机构:[1]Geriatric Hospital Afliated to Wuhan University of Science and Technology, Wuhan, China[2]Brain Science and Advanced Technology Institute, School of Medicine, Wuhan University of Science and Technology, Wuhan, China[3]School of Public Health, Wuhan University of Science and Technology, Wuhan, China[4]Department of Neurology and National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China[*1]Brain Science and Advanced Technology Institute, School of Medicine, Wuhan University of Science and Technology, West Huangjiahu Road, Hongshan District, Wuhan 430065, China[*2]Department of Neurology and National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Huashan Hospital, Shanghai Medical College, Fudan University, 12th Wulumuqi Zhong Road, Shanghai 200040, China[*3]Geriatric Hospital Afliated to Wuhan University of Science and Technology, West Huangjiahu Road, Hongshan District, Wuhan 430065, China
推荐引用方式(GB/T 7714):
S.-Y. Li,X.-Y. Xie,D. Liu,et al.China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress[J].JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE.2024,11(3):589-600.doi:10.14283/jpad.2024.63.
APA:
S.-Y. Li,X.-Y. Xie,D. Liu,G.-R. Cheng,F.-F. Hu...&Y. Zeng.(2024).China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress.JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE,11,(3)
MLA:
S.-Y. Li,et al."China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress".JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE 11..3(2024):589-600